155 related articles for article (PubMed ID: 34700018)
21. Effects of
Maeda A; Ando H; Irie K; Hashimoto N; Morishige JI; Fukushima S; Ebi H; Uchida K; Iwata H; Sawaki M
Anticancer Res; 2023 Mar; 43(3):1283-1289. PubMed ID: 36854511
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
Wang J; Gan C; Sparidans RW; Wagenaar E; van Hoppe S; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Mar; 129():414-423. PubMed ID: 29155017
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract][Full Text] [Related]
24. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
25. P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).
Wang Y; Sparidans RW; Potters S; Şentürk R; Lebre MC; Beijnen JH; Schinkel AH
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832869
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
[TBL] [Abstract][Full Text] [Related]
27. Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.
F Martins ML; Heydari P; Li W; Martínez-Chávez A; Venekamp N; Lebre MC; Lucas L; Beijnen JH; Schinkel AH
Front Pharmacol; 2022; 13():855000. PubMed ID: 35308219
[TBL] [Abstract][Full Text] [Related]
28. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
29. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice.
F Martins ML; Loos NHC; El Yattouti M; Offeringa L; Heydari P; Hillebrand MJX; Lebre MC; Beijnen JH; Schinkel AH
Pharm Res; 2023 Aug; 40(8):1885-1899. PubMed ID: 37344602
[TBL] [Abstract][Full Text] [Related]
31. ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.
Li W; Sparidans RW; Lebre MC; Beijnen JH; Schinkel AH
Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834176
[TBL] [Abstract][Full Text] [Related]
32. Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice.
Song YK; Kim MJ; Kim MS; Lee JH; Chung SJ; Song JS; Chae YJ; Lee KR
Eur J Pharm Sci; 2022 Jun; 173():106177. PubMed ID: 35341895
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
Tang SC; Sparidans RW; Cheung KL; Fukami T; Durmus S; Wagenaar E; Yokoi T; van Vlijmen BJ; Beijnen JH; Schinkel AH
Clin Cancer Res; 2014 Jun; 20(12):3133-45. PubMed ID: 24727322
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
Tang SC; Kort A; Cheung KL; Rosing H; Fukami T; Durmus S; Wagenaar E; Hendrikx JJ; Nakajima M; van Vlijmen BJ; Beijnen JH; Schinkel AH
Mol Pharm; 2015 Oct; 12(10):3714-23. PubMed ID: 26317243
[TBL] [Abstract][Full Text] [Related]
36. Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.
Traxl A; Wanek T; Mairinger S; Stanek J; Filip T; Sauberer M; Müller M; Kuntner C; Langer O
J Nucl Med; 2015 Dec; 56(12):1930-6. PubMed ID: 26359257
[TBL] [Abstract][Full Text] [Related]
37. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
[TBL] [Abstract][Full Text] [Related]
38. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
39. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure.
Wang J; Susam MM; Gan C; Sparidans RW; Lebre MC; Beijnen JH; Schinkel AH
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145346
[TBL] [Abstract][Full Text] [Related]
40. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]